Moitrayee Bhattacharyya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Moitrayee Bhattacharyya has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Mandar Deepak Muzumdar
Yale Cancer Biology Institute, Yale University , West Haven, CT 06516
18 shared publications - Wenxue Li
Yale Cancer Biology Institute, Yale University, West Haven, USA
18 shared publications - Xiangyu Ge
Yale University 1 Yale Cancer Biology Institute West Haven, Connecticut
18 shared publications - Yansheng Liu
Department of Pharmacology, Yale School of Medicine
18 shared publications - Cassandra Santaella Bishop
Yale University 1 Yale Cancer Biology Institute West Haven, Connecticut
17 shared publications - Christian Felipe Ruiz
Yale University 1 Yale Cancer Biology Institute West Haven, Connecticut
17 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Table S3 shows differential biotinylated protein abundance with PI3K activity modulation.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Table S3 shows differential biotinylated protein abundance with PI3K activity modulation.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Table S1 shows PI3K inhibitor sensitivity across KRAS variants in isogenic PDAC cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Table S1 shows PI3K inhibitor sensitivity across KRAS variants in isogenic PDAC cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S1 shows that PI3K regulates MAPK signaling in RAS wild-type cells across RAS isoforms and cancer types.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S1 shows that PI3K regulates MAPK signaling in RAS wild-type cells across RAS isoforms and cancer types.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S6 shows that protein proximity labeling using MiniTurbo identifies PI3K-dependent KRAS interactors.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S6 shows that protein proximity labeling using MiniTurbo identifies PI3K-dependent KRAS interactors.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S3 shows that PI3K selectively regulates wild-type but not mutant RAS activity.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S3 shows that PI3K selectively regulates wild-type but not mutant RAS activity.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Table S2 shows protein proximity labeling proteomics data.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Table S2 shows protein proximity labeling proteomics data.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S10 shows that PI3K inhibition overcomes acquired resistance to KRAS inhibition in PDAC cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S10 shows that PI3K inhibition overcomes acquired resistance to KRAS inhibition in PDAC cells.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Despite the availability of RAS inhibitors and the dependence of >90% of pancreatic ductal adenocarcinomas (PDAC) on oncogenic KRAS mutations, resistance to KRAS inhibition remains a serious obstacle. We showed here that phosphoinositide 3-kinase (PI3K) plays a major role in this resistance through upstream activation of wild-type (WT) RAS signaling—beyond its known KRAS effector function. The combination of proximity labeling, CRISPR screening, live-cell imaging, and functional assays revealed that PI3K orchestrates phosphoinositide-mediated GAB1 recruitment to the plasma membrane, nucleating assembly of RAS signaling complexes that activate mitogen-activated protein kinase (MAPK) in an EGFR/SHP2/SOS1-dependent manner. Inhibiting PI3K enhanced sensitivity to mutant-specific KRAS inhibitors in PDAC cells, including in cells with clinically identified PIK3CA mutations. These findings refine RAS–PI3K signaling paradigms, reveal that PI3K-driven WT RAS activation drives resistance to KRAS inhibition, and illuminate avenues for augmenting KRAS-targeted therapies in PDAC. Significance:PI3K plays a functional upstream role in assembling wild-type RAS signaling complexes that confer KRAS inhibitor resistance, providing a rationale for combined targeting of PI3K and KRAS in pancreatic cancer.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Despite the availability of RAS inhibitors and the dependence of >90% of pancreatic ductal adenocarcinomas (PDAC) on oncogenic KRAS mutations, resistance to KRAS inhibition remains a serious obstacle. We showed here that phosphoinositide 3-kinase (PI3K) plays a major role in this resistance through upstream activation of wild-type (WT) RAS signaling—beyond its known KRAS effector function. The combination of proximity labeling, CRISPR screening, live-cell imaging, and functional assays revealed that PI3K orchestrates phosphoinositide-mediated GAB1 recruitment to the plasma membrane, nucleating assembly of RAS signaling complexes that activate mitogen-activated protein kinase (MAPK) in an EGFR/SHP2/SOS1-dependent manner. Inhibiting PI3K enhanced sensitivity to mutant-specific KRAS inhibitors in PDAC cells, including in cells with clinically identified PIK3CA mutations. These findings refine RAS–PI3K signaling paradigms, reveal that PI3K-driven WT RAS activation drives resistance to KRAS inhibition, and illuminate avenues for augmenting KRAS-targeted therapies in PDAC. Significance:PI3K plays a functional upstream role in assembling wild-type RAS signaling complexes that confer KRAS inhibitor resistance, providing a rationale for combined targeting of PI3K and KRAS in pancreatic cancer.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S5 shows that protein proximity labeling identifies PI3K-dependent KRAS interactors.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S5 shows that protein proximity labeling identifies PI3K-dependent KRAS interactors.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S8 shows temporal dynamics of PI3K and MAPK signaling following KRAS inhibition in PDAC cells.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Supplementary Figure S8 shows temporal dynamics of PI3K and MAPK signaling following KRAS inhibition in PDAC cells.